<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T08:12:15Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27851" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27851</identifier><datestamp>2026-09-24T02:08:14Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Rullo, Anthony</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Eisinga, Sarah</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Chemical Biology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-09-25T15:48:08Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-09-25T15:48:08Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27851</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/10392</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Covalent antibody recruiting molecules (cARMs) are synthetic chemical tools that direct&#xd;
antibodies naturally present in human serum to tumor receptors leading to immune recognition&#xd;
and elimination. cARMs have three general features: an antibody binding domain (ABD), an&#xd;
antibody labelling domain (ALD), and a tumor binding domain. Proximal to the ABD, the ALD&#xd;
contains an electrophilic group which is attacked by a nucleophilic amino acid residue on the&#xd;
target antibody upon cARM binding. Previous cARMs use an acyl-imidazole (AL) ALD to&#xd;
successfully covalently recruit anti-dinitrophenyl IgG validated via fluorescence SDS-PAGE,and&#xd;
form immune complexes with PSMA+ HEK cells in ADCP flow experiments.1 Through MS&#xd;
analysis, AL cARMs were demonstrated to target lysine-59 of antiDNP.1 Problematically, there&#xd;
are several properties associated with AL chemistry that limit the therapeutic potential of&#xd;
associated cARMs. These limitations include limited stability in vivo, single amino acid (lysine)&#xd;
selectivity, and modest intramolecular protein labelling rates (10-5 s-1)1. To target novel antibody&#xd;
residues and possibly improve the rate of antibody labelling, a second generation of cARMs has&#xd;
been developed using sulfur fluoride exchange (SuFEx) chemistry as the ALD. Sulfur fluorides&#xd;
have been broadly used in academic and industrial applications due to intrinsically high stability&#xd;
and broad amino acid reactivity.2 SuFEx cARMs are hypothesized to have enhanced hydrolytic&#xd;
stability compared to AL cARMs. This thesis explores the synthesis, stability, binding, and&#xd;
labeling kinetics of SuFEx cARMs to advance cARM design and development for in vivo&#xd;
applications. This research contributes collectively to the design and development of novel&#xd;
therapeutics in chemical biology and immune-oncology research.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">sulfur fluoride</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Optimizing Covalent Immune Recruiter Antibody Labelling Kinetics with Sulfur Fluoride Exchange Chemistry</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>